UBS AG has raised its price target for Netflix from $825 to $1,040 while maintaining a "Buy" rating. Analyst John Hodulik noted that Netflix is poised to benefit significantly from the ongoing structural changes in the media sector, leading to increased long-term estimates for operating profit and cash flow.
Bitcoin's surge has prompted Australian fund managers to increase their Ethereum allocations, anticipating a significant rise in its value. While Bitcoin has soared nearly 70% above its 2021 peak, Ethereum struggles below $4,000, despite institutional support through multiple ETFs. Investors believe Ethereum's performance will improve, with expectations of reaching $6,000 or $8,000 if Bitcoin hits $150,000.
Nolus, a DeFi lending platform, has seen its total value locked surge fivefold to $5 million, driven by its innovative Smart Leverage feature that allows users to amplify their crypto exposure with partial collateralization. The platform's recent buyback of 4 million NLS tokens aims to enhance token value and sustainability, reflecting its commitment to a resilient DeFi ecosystem. With adaptive strategies like partial liquidations, Nolus effectively mitigates risks during market volatility, positioning itself for future growth.
Deus Wallet has launched a groundbreaking 'duress mode' feature to enhance cryptocurrency security against physical threats. This innovative tool allows users to set a secondary PIN that, when entered under coercion, opens a decoy account, keeping actual assets hidden. With a non-custodial architecture, Deus Wallet ensures users maintain full control over their private keys, addressing both digital and physical security challenges in the evolving crypto landscape.
Deutsche Bank is developing a layer-2 blockchain solution for Ethereum to tackle regulatory challenges faced by financial institutions using public blockchains. This initiative, part of Project Dama 2 under Singapore's MAS Project Guardian, aims to mitigate risks such as transaction validation and fees to sanctioned entities. The bank plans to launch a minimum viable product next year, allowing for a curated list of validators and enhanced regulatory oversight.
Fartcoin, a memecoin lacking utility, briefly surpassed a $1 billion market cap on December 18, despite a broader crypto market slump. This surge followed a U.S. Federal Reserve rate cut announcement, prompting investors to seek alternatives amid uncertainty. The coin's volatility has sparked both humor and concern regarding the state of the crypto market.
UBS will relocate its Brugg branch to Hauptstrasse 1 on January 13, 2025, consolidating around 180 employees from various units. The move follows the acquisition of Credit Suisse, with plans for a shared space between UBS and the city administration after the transition. Meanwhile, the former UBS location at Bahnhofstrasse 11 is being marketed for new tenants.
Rexas Finance (RXS) is emerging as a promising investment alternative to Dogecoin, focusing on democratizing asset ownership through real-world asset tokenization. With a successful presale raising over $28 million and plans for a public listing in early 2025, RXS tokens are projected to surge significantly, potentially reaching $5, far surpassing Dogecoin's speculative growth. The initiative emphasizes transparency and community engagement, positioning itself as a transformative force in the blockchain space.
Ethereum experienced a significant decline, trading at $3,473.09, down 10.31% on the day, marking its largest one-day loss since November 2022. This drop reduced its market cap to $423.79 billion, representing 12.41% of the total cryptocurrency market. Over the past week, Ethereum's value has decreased by 10.78%, and it remains 28.60% below its all-time high of $4,864.06 from November 2021.
Novartis will close two MorphoSys sites in Germany and the US, resulting in approximately 330 job losses, following delays in the pelabresib program. The decision comes after mixed results in a phase 3 trial for the blood disorder myelofibrosis, prompting a potential filing delay until 2027. Despite challenges, Novartis remains committed to the drug, which it previously deemed "practice-changing."

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings